基因组癌症检测及分析市场－全球产业规模、份额、趋势、机会及预测：组织检测、癌症检测类型、癌症类型、应用、技术、终端用户、地区及竞争格局，2021-2031年

全球基因组癌症检测和分析市场预计将从 2025 年的 110.9 亿美元增长到 2031 年的 191.6 亿美元，复合年增长率为 9.54%。

这些诊断技术专注于对特定基因或基因组区域定序，以识别驱动肿瘤发生的突变和变化。市场成长趋势的主要驱动因素是全球癌症发生率的上升（这需要个人化的治疗策略）以及次世代定序工作流程成本的下降。这些因素共同推动了分子诊断在临床实践中的广泛应用，以优化标靶治疗方案。

日益加重的疾病负担进一步推动了这项需求。美国癌症协会预测，到2024年，美国新增癌症病例将首次超过200万例。儘管需求如此明确，但市场仍面临与复杂的报销结构相关的重大障碍。全面的分子谱分析保险覆盖范围不一致仍然是一个主要障碍，这可能会阻碍其广泛应用，并限制患者获得这些重要的检测服务。

市场驱动因素

非侵入性液态生物检体活检技术的快速发展是推动市场成长的主要动力，它克服了传统组织取样的限制。这些基于血液的检测方法能够检测循环肿瘤DNA，从而实现对疾病进展和抗药性机制的即时追踪，且无需承担手术切片检查的风险。临床检测量的成长也印证了微创诊断技术的普及。例如，Guardant Health在2024年11月发布的第三季财报中宣布，其临床检测量年增21%，达到53,100例，显示这些技术在临床应用中正迅速普及。

同时，生物标记主导的药物研发兴起，推动了对综合基因组检测的需求，以识别标靶治疗候选药物。製药公司正大力投资精准肿瘤产品组合，推动了伴随诊断的需求。例如，辉瑞在2024年第三季财报（2024年10月）中指出，收购Seegen的产品组合为其肿瘤部门贡献了8.54亿美元的收入，这体现了生物标誌物标标靶治疗的商业性价值。这项投资也与疾病负担的长期预测相符。世界卫生组织（WHO）下属的国际癌症研究机构（IARC）在2024年预测，到2050年，全球癌症患者人数将超过3500万，凸显了可扩展诊断解决方案的迫切性。

市场挑战

复杂的报销环境和参差不齐的保险覆盖范围对全球基因组癌症检测和分析市场的扩张构成了重大障碍。当支付结构不明确或难以预测时，临床实验室和医院系统往往不愿意将全面的基因组分析纳入常规诊疗流程。这种财务上的不确定性迫使医疗机构依赖范围更窄、成本更低的诊断测试以避免拒付，阻碍了广泛的次世代定序检测的普及。因此，医疗机构的财务管理人员通常认为这些先进诊断技术的经济风险超过了其临床效益，限制了市场扩张。

此外，支付方政策的不一致限制了诊断公司的整体检测量和商机。由于缺乏标准化的强制规定，患者往往面临高昂的自付费用和较高的检测中止率。根据美国癌症协会癌症行动网络（American Cancer Society Cancer Action Network）统计，截至2024年，仅有16个州颁布了法律，保障全面的生物标记检测，这意味着美国大部分人口仍面临分散且限制性强的保险选择。这种监管碎片化导致市场结构依赖地域条件和保险计划类型，而非临床需求，从而有效地抑制了市场渗透和成长。

市场趋势

将人工智慧 (AI) 应用于数据解读正在改变市场格局，有效应对海量基因组数据集的分析挑战。随着定序结果日益复杂，AI 演算法对于获取临床洞见和检测人工分析可能遗漏的罕见突变模式至关重要。这种技术融合正在推动商业性应用，诊断公司正利用 AI 来提升精准医疗能力并提高营运效率。例如，Tempus AI 在 2025 年 1 月发布的「2024 财年第四季及全年初步业绩」中报告称，全年营收约为 6.93 亿美元，同比增长 30%。这一成长主要得益于该公司 AI 驱动的精准医疗和基因组分析解决方案的广泛应用。

同时，市场正经历着向全面基因组分析（CGP）的明显转变，从窄范围的热点基因panel转向广谱定序。这项转变的驱动力来自新兴的临床数据，这些数据表明，与窄范围的诊断方法相比，大规模的panel能够识别出更多可靶向的突变，并提高患者获得适当治疗方法。这一显着的临床优势正促使医疗系统将更广泛的检测通讯协定标准化，以确保不错过任何治疗机会。正如Illumina在2024年11月关于此次合作的新闻稿中所指出的，真实世界数据显示，接受CGP检测的患者中，67%的肿瘤携带可靶向的突变，而接受50基因panel检测的患者中，这一比例仅为33%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球基因组癌症检测及分析市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过组织检测（固态组织检测、液体组织检测）
  • 依癌症检测组合类型（单基因检测、多基因检测）
  • 癌症类型（肺癌、乳癌、结肠癌、摄护腺癌、其他）
  • 按应用领域（临床、研究）
  • 依技术分类（次世代定序（NGS）、聚合酵素链锁反应（PCR）、萤光原位杂合反应（FISH）、免疫组织化学（IHC）、其他）
  • 依最终使用者（医院、临床/诊断检查室、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美基因组癌症检测及分析市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲基因组癌症检测及分析市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区基因组癌症检测及分析市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东及非洲基因组癌症检测及分析市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲基因组癌症检测及分析市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球基因组癌症检测及分析市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies, Inc.
• ARUP Laboratories Inc
• Burning Rock Biotech Limited
• US Caris MPI, Inc.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Fulgent Genetics Inc.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Genomic Cancer Panel & Profiling Market is projected to expand from a valuation of USD 11.09 Billion in 2025 to USD 19.16 Billion by 2031, registering a CAGR of 9.54%. These diagnostic technologies focus on sequencing specific genes or genomic regions to pinpoint mutations and alterations that fuel tumor development. The market's upward trajectory is largely driven by the growing global incidence of cancer, which demands personalized therapeutic strategies, alongside the decreasing costs associated with next-generation sequencing workflows. Together, these factors encourage the incorporation of extensive molecular diagnostics into clinical settings to optimize targeted treatment planning.

This demand is intensified by the increasing disease burden; the American Cancer Society projects that new cancer cases in the United States will exceed 2 million for the first time in 2024. Despite this evident need, the market contends with significant hurdles related to complex reimbursement structures. Inconsistent insurance coverage for comprehensive molecular profiling continues to be a major obstacle, potentially limiting widespread adoption and restricting patient access to these critical testing capabilities.

Market Driver

The rapid growth of non-invasive liquid biopsy profiling serves as a major market accelerator by addressing the constraints of conventional tissue sampling. These blood-based assays facilitate the detection of circulating tumor DNA, allowing for real-time tracking of disease progression and resistance mechanisms without the dangers linked to surgical biopsies. The shift toward less invasive diagnostics is underscored by increasing clinical testing volumes; for instance, Guardant Health reported in its November 2024 Third Quarter Financial Results that clinical test volume rose 21% year-over-year to 53,100 tests, signaling rapid clinical adoption of these tools.

Concurrently, the rise in biomarker-driven drug development requires the use of comprehensive genomic panels to identify candidates for targeted therapies. Pharmaceutical companies are heavily investing in precision oncology portfolios, fueling the need for companion diagnostics. Highlighting the commercial value of biomarker-targeted treatments, Pfizer reported in its October 2024 Third Quarter Results that oncology revenue was bolstered by an $854 million contribution from the acquired Seagen portfolio. This investment aligns with long-term forecasts of disease burden, as the World Health Organization's International Agency for Research on Cancer predicted in 2024 that global cancer cases will exceed 35 million by 2050, emphasizing the urgency for scalable diagnostic solutions.

Market Challenge

Complicated reimbursement landscapes and inconsistent insurance coverage represent substantial obstacles to the expansion of the Global Genomic Cancer Panel & Profiling Market. Clinical laboratories and hospital systems are often reluctant to incorporate comprehensive genomic profiling into routine care when payment structures are unclear or unpredictable. This financial instability forces healthcare providers to depend on narrower, less costly diagnostic tests to prevent claim denials, which hinders the uptake of broader next-generation sequencing panels. Consequently, market expansion is stifled because financial administrators at medical facilities often view the economic risks of these advanced diagnostics as outweighing their clinical benefits.

Furthermore, the lack of uniformity in payer policies limits the total volume of testing and restricts revenue opportunities for diagnostic firms. Without standardized mandates, patients frequently encounter prohibitive out-of-pocket expenses, resulting in high rates of test abandonment. According to the American Cancer Society Cancer Action Network in 2024, only 16 states had enacted legislation guaranteeing coverage for comprehensive biomarker testing, leaving most of the United States population facing fragmented and restrictive insurance decisions. This regulatory patchwork creates a market where access depends more on geography and insurance plan type than on clinical necessity, effectively capping market penetration and growth.

Market Trends

The integration of Artificial Intelligence in Data Interpretation is transforming the market by addressing the challenge of analyzing vast genomic datasets. As sequencing outputs increase in complexity, AI algorithms have become crucial for deriving clinical insights and detecting rare variant patterns that might be overlooked during manual analysis. This technological convergence is driving commercial adoption, with diagnostic companies utilizing AI to refine precision medicine capabilities and boost operational efficiency. For example, Tempus AI reported in its January 2025 Preliminary Fourth Quarter and Full Year 2024 Results that full-year revenue reached approximately $693 million, marking a 30% year-over-year increase attributed largely to the strong adoption of its AI-powered precision medicine and genomic profiling solutions.

At the same time, the market is undergoing a distinct transition toward Comprehensive Genomic Profiling (CGP), moving away from limited hotspot panels in favor of broad-spectrum sequencing. This evolution is driven by emerging clinical data indicating that larger panels identify a significantly higher number of actionable alterations, thereby enhancing patient access to matched therapies relative to narrower diagnostic methods. This distinct clinical advantage is prompting healthcare systems to standardize broader testing protocols to reduce missed treatment opportunities. As noted by Illumina in a November 2024 press release regarding a new joint study, real-world evidence showed that 67% of tumors from CGP-tested patients contained actionable mutations, compared to just 33% in patients assessed with smaller 50-gene panels.

Key Market Players

• Agilent Technologies, Inc.
• ARUP Laboratories Inc
• Burning Rock Biotech Limited
• U.S. Caris MPI, Inc.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Fulgent Genetics Inc.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomic Cancer Panel & Profiling Market, By Tissue Testing

• Solid Tissue Testing
• Liquid Tissue Testing

Genomic Cancer Panel & Profiling Market, By Cancer Panel Type

• Single-Gene Panel
• Multi-Gene Panel

Genomic Cancer Panel & Profiling Market, By Cancer Type

• Lung Cancer
• Breast Cancer
• Colon Cancer
• Prostate Cancer
• Others

Genomic Cancer Panel & Profiling Market, By Application

• Clinical
• Research

Genomic Cancer Panel & Profiling Market, By Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescence In-Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Others

Genomic Cancer Panel & Profiling Market, By End-User

• Hospitals
• Clinical and Diagnostic Laboratories
• Others

Genomic Cancer Panel & Profiling Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomic Cancer Panel & Profiling Market.

Available Customizations:

Global Genomic Cancer Panel & Profiling Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomic Cancer Panel & Profiling Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
  • 5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
  • 5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
  • 5.2.4. By Application (Clinical, Research)
  • 5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
  • 5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2025)
• 5.3. Market Map

6. North America Genomic Cancer Panel & Profiling Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tissue Testing
  • 6.2.2. By Cancer Panel Type
  • 6.2.3. By Cancer Type
  • 6.2.4. By Application
  • 6.2.5. By Technology
  • 6.2.6. By End-User
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tissue Testing
      • 6.3.1.2.2. By Cancer Panel Type
      • 6.3.1.2.3. By Cancer Type
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By Technology
      • 6.3.1.2.6. By End-User
  • 6.3.2. Canada Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tissue Testing
      • 6.3.2.2.2. By Cancer Panel Type
      • 6.3.2.2.3. By Cancer Type
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By Technology
      • 6.3.2.2.6. By End-User
  • 6.3.3. Mexico Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tissue Testing
      • 6.3.3.2.2. By Cancer Panel Type
      • 6.3.3.2.3. By Cancer Type
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By Technology
      • 6.3.3.2.6. By End-User

7. Europe Genomic Cancer Panel & Profiling Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tissue Testing
  • 7.2.2. By Cancer Panel Type
  • 7.2.3. By Cancer Type
  • 7.2.4. By Application
  • 7.2.5. By Technology
  • 7.2.6. By End-User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tissue Testing
      • 7.3.1.2.2. By Cancer Panel Type
      • 7.3.1.2.3. By Cancer Type
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By Technology
      • 7.3.1.2.6. By End-User
  • 7.3.2. France Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tissue Testing
      • 7.3.2.2.2. By Cancer Panel Type
      • 7.3.2.2.3. By Cancer Type
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By Technology
      • 7.3.2.2.6. By End-User
  • 7.3.3. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tissue Testing
      • 7.3.3.2.2. By Cancer Panel Type
      • 7.3.3.2.3. By Cancer Type
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By Technology
      • 7.3.3.2.6. By End-User
  • 7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tissue Testing
      • 7.3.4.2.2. By Cancer Panel Type
      • 7.3.4.2.3. By Cancer Type
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By Technology
      • 7.3.4.2.6. By End-User
  • 7.3.5. Spain Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tissue Testing
      • 7.3.5.2.2. By Cancer Panel Type
      • 7.3.5.2.3. By Cancer Type
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By Technology
      • 7.3.5.2.6. By End-User

8. Asia Pacific Genomic Cancer Panel & Profiling Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tissue Testing
  • 8.2.2. By Cancer Panel Type
  • 8.2.3. By Cancer Type
  • 8.2.4. By Application
  • 8.2.5. By Technology
  • 8.2.6. By End-User
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tissue Testing
      • 8.3.1.2.2. By Cancer Panel Type
      • 8.3.1.2.3. By Cancer Type
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By Technology
      • 8.3.1.2.6. By End-User
  • 8.3.2. India Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tissue Testing
      • 8.3.2.2.2. By Cancer Panel Type
      • 8.3.2.2.3. By Cancer Type
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By Technology
      • 8.3.2.2.6. By End-User
  • 8.3.3. Japan Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tissue Testing
      • 8.3.3.2.2. By Cancer Panel Type
      • 8.3.3.2.3. By Cancer Type
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By Technology
      • 8.3.3.2.6. By End-User
  • 8.3.4. South Korea Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Tissue Testing
      • 8.3.4.2.2. By Cancer Panel Type
      • 8.3.4.2.3. By Cancer Type
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By Technology
      • 8.3.4.2.6. By End-User
  • 8.3.5. Australia Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Tissue Testing
      • 8.3.5.2.2. By Cancer Panel Type
      • 8.3.5.2.3. By Cancer Type
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By Technology
      • 8.3.5.2.6. By End-User

9. Middle East & Africa Genomic Cancer Panel & Profiling Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tissue Testing
  • 9.2.2. By Cancer Panel Type
  • 9.2.3. By Cancer Type
  • 9.2.4. By Application
  • 9.2.5. By Technology
  • 9.2.6. By End-User
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tissue Testing
      • 9.3.1.2.2. By Cancer Panel Type
      • 9.3.1.2.3. By Cancer Type
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By Technology
      • 9.3.1.2.6. By End-User
  • 9.3.2. UAE Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tissue Testing
      • 9.3.2.2.2. By Cancer Panel Type
      • 9.3.2.2.3. By Cancer Type
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By Technology
      • 9.3.2.2.6. By End-User
  • 9.3.3. South Africa Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tissue Testing
      • 9.3.3.2.2. By Cancer Panel Type
      • 9.3.3.2.3. By Cancer Type
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By Technology
      • 9.3.3.2.6. By End-User

10. South America Genomic Cancer Panel & Profiling Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tissue Testing
  • 10.2.2. By Cancer Panel Type
  • 10.2.3. By Cancer Type
  • 10.2.4. By Application
  • 10.2.5. By Technology
  • 10.2.6. By End-User
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tissue Testing
      • 10.3.1.2.2. By Cancer Panel Type
      • 10.3.1.2.3. By Cancer Type
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By Technology
      • 10.3.1.2.6. By End-User
  • 10.3.2. Colombia Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tissue Testing
      • 10.3.2.2.2. By Cancer Panel Type
      • 10.3.2.2.3. By Cancer Type
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By Technology
      • 10.3.2.2.6. By End-User
  • 10.3.3. Argentina Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tissue Testing
      • 10.3.3.2.2. By Cancer Panel Type
      • 10.3.3.2.3. By Cancer Type
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By Technology
      • 10.3.3.2.6. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genomic Cancer Panel & Profiling Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ARUP Laboratories Inc
• 15.3. Burning Rock Biotech Limited
• 15.4. U.S. Caris MPI, Inc.
• 15.5. Danaher Corporation
• 15.6. Exact Sciences Corporation
• 15.7. F. Hoffmann-La Roche Ltd
• 15.8. Fulgent Genetics Inc.
• 15.9. Illumina, Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer